相关实验视频

Updated: Jul 19, 2026

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

治疗Enfortumab Vedotin治疗的晚期尿癌患者的风险分类

Gaku Ishikawa¹, Yuto Matsushita¹, Yuichi Kitagawa²

¹Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Cancer diagnosis & prognosis

|November 6, 2024

概括

高C反应蛋白和高血症预测了使用恩福图马布维多丁 (EV) 治疗的晚期泌尿腺癌患者的结果. 使用这些因素的新风险模型改善了这种癌症治疗的结果预测.

科学领域:

在瘤学瘤学.
医学科学医学科学医学科学

背景情况:

恩福图马布维多丁 (EV) 是高级泌尿器官癌 (UC) 后化疗和免疫疗法的关键治疗方法.
对于接受EV的患者的预后因素和风险分层存在有限的数据.
确定预测因素对于优化治疗策略至关重要.

研究的目的:

为了确定治疗EV的晚期UC患者的临床预后因素.
根据这些因素开发和验证一种新的风险分类模型.

主要方法:

一个多中心的回顾性研究中,先进的UC患者接受了EV治疗.
评估无进展生存期 (PFS) 和整体生存期 (OS).
预后因素的调查和风险分类模型的验证.

主要成果:

中位数PFS为7.1个月,中位数OS为16.3个月.
较高的C-反应蛋白 (CRP≥0.5 mg/dl) 和高血症 (>10.2 mg/dl) 是PFS和OS的显著负面预后因素.
一个三组风险分类模型显示了PFS和OS的显著差异 (c指数:PFS 0.766,OS 0.800).

结论:

开发的风险分类模型包含CRP和高血症,有效预测了EV治疗的晚期UC患者的结果.
这种模型有助于对患者进行分层,并预测治疗反应.

关键词:

在此之前,Enfortumab Vedotin 已经被推出.预后因素是一个预后因素.风险分类风险分类风险分类

更多相关视频

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Published on: November 22, 2019

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

相关概念视频

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...